Novartis : CAR-T cell therapy CTL019 unanimously 10-0 recommended for approval by FDA advisory committee to treat pediatric, youthful adult r/r B-cell ALL

By a News Reporter-Staff News Editor at Cancer Vaccine Week — Novartis announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory (r/r) pediatric and youthful adult patients with B-cell acute lymphoblastic leukemia (ALL) (see also Pharmaceutical Companies). Continue reading →